Menotropins trials evaluate named, standardized fertility medicines within monitored protocols. Their outcomes cannot be transferred to an undefined hMG mixture or reduced to a generic FSH-plus-LH claim.
Evidence at a glance
- A 620-participant trial compared highly purified hMG with recombinant FSH in predicted high responders.
- Ongoing pregnancy was 35.5% versus 30.7%; the difference was 4.7 percentage points with a 95% CI from −2.7 to 12.1.
- OHSS occurred in 9.7% versus 21.4%, while cumulative live birth was 50.6% versus 51.5%.
Study record
The high-responder trial preserved several outcomes rather than reporting only pregnancy. Similar cumulative live birth alongside different OHSS rates shows why both benefit and safety endpoints belong in the summary.
Results in context
In a separate WHO group II anovulatory-infertility trial, ovulation rates were almost identical. OHSS or excessive-response cancellation was 2.2% versus 9.8% with p=0.058; that p value should not be rewritten as a definitive difference.
DailyMed describes Menopur as postmenopausal-urine-derived material containing 75 IU FSH and 75 IU LH activity per vial, with hCG detectable. The label and trial findings apply to that regulated preparation and monitored use.
What the evidence cannot establish
Open-label designs and selected fertility populations limit generalization.
Pregnancy, live birth and OHSS should not be collapsed into one efficacy score.
Trial evidence for Menopur or another named product does not validate research hMG.
Sources & editorial method
This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, sample size, model/population limits, finished-drug scope, regulatory status and product-evidence boundaries are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- DailyMed Menopur labelOfficial product description, potency, source and safety context.
- Highly purified hMG versus recombinant FSH in high responders620-participant randomized noninferiority trial; PMID 32416978.
- HP-hMG versus recombinant FSH in WHO group II infertility184-participant randomized trial; PMID 16571641.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
